Background: Accurate risk assessment for carcinogens requires an understanding of the link between the presence of the chemical in human tissues and the resulting biological effects of the exposure. New methods are being developed to measure the phenotypic effects of exposure and for studying genetic changes that may be directly in the pathway of the disease process. In addition, discovery of new genes in environmental response pathways and new polymorphisms in these response pathways has become an important focus.
Aims : Develop technology and capacity for: 1) discovery of genes expressed as a result of exposure, 2) quantitative measurement of exposure-induced expression 3) detection of germline polymorphism 4) genotype/phenotype comparisons 5) Bioinformatic derived genetic markers. Accomplishments: 1) Discovery/characterization of functional polymorphisms in CYP2E1 and UGT1A1 promoters (1).2) Polymorphism in the XRCC1 gene appears to be related to higher frequency of glycophorin A mutations among smokers (2). 3) XPD polymorphism was associated with greater sensitivity to X-ray induced chromatid aberrations and family history of breast cancer (4).4) We observed that among smokers GSTT1 null polymorphism results in ~2-fold higher levels of ethylene oxide-hemoglobin adducts in erythrocytes (5).5) Developed exposure model using lymphoblastoid cell lines and test with cDNA microarray analysis of gene expression following exposure to agents that initiate base excision repair and nucleotide excision repair. 6) Highly sensitive quantitative PCR methods (Taqman) have been developed to monitor CYP1A1 (PAH inducible), CYP1B1, GSTP1, COX2, GADD45, GADD153 (cell cycle arrest/damage inducible) expression and these methods will be used to independently verify inducibility (positive controls).7) Bioinformatics - A combinatorial genomic methodology for identifying unique markers from whole genomes has been developed and is the subject of an employee invention report.Significance: Development of these biomarker techniques will allow us to test hypotheses concerning the role of environmental and genetic factors in understanding the etiology of human disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES090604-04
Application #
6432434
Study Section
(LCBR)
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2000
Total Cost
Indirect Cost
Name
U.S. National Inst of Environ Hlth Scis
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Liu, Xuemei; Campbell, Michelle R; Pittman, Gary S et al. (2005) Expression-based discovery of variation in the human glutathione S-transferase M3 promoter and functional analysis in a glioma cell line using allele-specific chromatin immunoprecipitation. Cancer Res 65:99-104
Wang, Xuting; Tomso, Daniel J; Liu, Xuemei et al. (2005) Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. Toxicol Appl Pharmacol 207:84-90
Lee, Su-Jun; Bell, Douglas A; Coulter, Sherry J et al. (2005) Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 313:302-9
Grant, Delores J; Hall, Ingrid J; Eastmond, David A et al. (2004) Bilirubin UDP-glucuronosyltransferase 1A1 (UGT1A1) gene promoter polymorphisms and HPRT, glycophorin A, and micronuclei mutant frequencies in human blood. Mutat Res 560:1-10
Mammen, Jennifer S; Pittman, Gary S; Li, Ying et al. (2003) Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis 24:1247-55
Fritsche, E; Baek, S J; King, L M et al. (2001) Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299:468-76
Grant, D J; Bell, D A (2000) Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: susceptibility to oxidative damage and cancer? Mol Carcinog 29:198-204